No profile data available.
Fulgent Genetics, Inc. (FLGT) is a healthcare company in the medical testing laboratories industry, based in El Monte, United States, with about 1,315 full-time employees.
It reported revenue of $322.67 million for fiscal year 2025, up 13.8% from fiscal year 2024, and net income of -$60.51 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $85.39 million, up 4.4% from a year before. Its largest business segment, Laboratory Services, brought in 100% of segment revenue in fiscal year 2025; United States was the largest region with 92%. Its market capitalization was $598.18 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Fulgent Genetics reported $322.67 million in revenue for fiscal year 2025, up 13.8% from $283.47 million in fiscal year 2024. In Q2 2026 revenue was $85.39 million.
Laboratory Services, with $322.22 million or 100% of segment revenue in fiscal year 2025. Next: Therapeutic Development (under 1%).
United States: 92% of revenue by region in fiscal year 2025, followed by Other Countries (4%).
$598.18 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medical testing laboratories) include GeneDx Holdings Corp. (WGS), NeoGenomics, Inc. (NEO), Opko Health, Inc. (OPK), Prenetics Global Limited (PRE).